[[Metabolite]]s of DHT have been found to act as [[neurosteroid]]s with their own AR-independent biological activity.<ref name="pmid22231829">{{cite journal | vauthors = Kohtz AS, Frye CA | title = Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models | journal = Methods Mol. Biol. | volume = 829 | issue = | pages = 397–431 | year = 2012 | pmid = 22231829 | doi = 10.1007/978-1-61779-458-2_26 | url = }}</ref> [[3α-Androstanediol]] is a potent [[positive allosteric modulator]] of the [[GABAA receptor|GABA<sub>A</sub> receptor]], while [[3β-androstanediol]] is a potent and [[binding selectivity|selective]] agonist of the [[estrogen receptor]] (ER) subtype [[ERβ]].<ref name="pmid22231829" /> These metabolites may play important roles in the [[central nervous system|central]] effects of DHT and by extension testosterone, including their [[antidepressant]], [[anxiolytic]], [[reward system|rewarding]]/[[hedonism|hedonic]], [[anti-stress]], and [[nootropic|pro-cognitive]] effects.<ref name="pmid22231829" /><ref name="pmid26259885">{{cite journal | vauthors = Brunton PJ | title = Neuroactive steroids and stress axis regulation: Pregnancy and beyond | journal = J. Steroid Biochem. Mol. Biol. | volume = 160 | issue = | pages = 160–8 | year = 2016 | pmid = 26259885 | doi = 10.1016/j.jsbmb.2015.08.003 | url = }}</ref>

 
5α-Reductase inhibitors are overall [[tolerability|well-tolerated]] and show a low incidence of [[adverse effect]]s.<ref name="pmid27672412">{{cite journal | vauthors = Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS | title = Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review | journal = J Clin Aesthet Dermatol | volume = 9 | issue = 7 | pages = 56–62 | year = 2016 | pmid = 27672412 | pmc = 5023004 | doi = | url = }}</ref> [[Sexual dysfunction]], including [[erectile dysfunction]], [[loss of libido]], and [[hypospermia|reduced ejaculate volume]], may occur in 3.4 to 15.8% of men treated with finasteride or dutasteride.<ref name="pmid27672412" /><ref name="pmid27475241">{{cite journal | vauthors = Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z | title = Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials | journal = J Sex Med | volume = 13 | issue = 9 | pages = 1297–310 | year = 2016 | pmid = 27475241 | doi = 10.1016/j.jsxm.2016.07.006 | url = }}</ref> A small increase in the risk of [[affective disorder|affective symptom]]s including [[depression (mood)|depression]], [[anxiety]], and [[self-harm]] may be seen.<ref name="pmid24955220" /><ref name="pmid28319231">{{cite journal | vauthors = Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S | title = Association of Suicidality and Depression With 5α-Reductase Inhibitors | journal = JAMA Intern Med | volume = 177 | issue = 5 | pages = 683–691 | year = 2017 | pmid = 28319231 | doi = 10.1001/jamainternmed.2017.0089 | url = }}</ref><ref name="pmid28319227">{{cite journal | vauthors = Thielke S | title = The Risk of Suicidality and Depression From 5-α Reductase Inhibitors | journal = JAMA Intern Med | volume = 177 | issue = 5 | pages = 691–692 | year = 2017 | pmid = 28319227 | doi = 10.1001/jamainternmed.2017.0096 | url = }}</ref> Both the sexual dysfunction and affective symptoms may be due partially or fully to prevention of the synthesis of [[neurosteroid]]s like [[allopregnanolone]] rather necessarily than due to inhibition of DHT production.<ref name="pmid24955220">{{cite journal | vauthors = Traish AM, Mulgaonkar A, Giordano N | title = The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression | journal = Korean J Urol | volume = 55 | issue = 6 | pages = 367–79 | year = 2014 | pmid = 24955220 | pmc = 4064044 | doi = 10.4111/kju.2014.55.6.367 | url = }}</ref> A very small risk of [[gynecomastia]] has been associated with 5α-reductase inhibitors (1.2 to 3.5%).<ref name="pmid27672412" /><ref name="pmid28232919">{{cite journal | vauthors = Fertig R, Shapiro J, Bergfeld W, Tosti A | title = Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome | journal = Skin Appendage Disord | volume = 2 | issue = 3-4 | pages = 120–129 | year = 2017 | pmid = 28232919 | pmc = 5264352 | doi = 10.1159/000450617 | url = }}</ref> Based on reports of 5α-reductase type II deficiency in males and the effectiveness of 5α-reductase inhibitors for hirsutism in women, reduced body and/or facial hair growth is a likely potential side effect of these drugs in men.<ref name="Blume-PeytaviWhiting2008" /><ref name="KatsambasLotti2015" /> There are very few studies evaluating the side effects of 5α-reductase inhibitors in women.<ref name="pmid27672412" /> However, due to the known role of DHT in male sexual differentiation, 5α-reductase inhibitors may cause [[birth defect]]s such as ambiguous genitalia in the male [[fetus]]es of [[pregnancy|pregnant]] women.<ref name="pmid27672412" /> As such, they are not used in women during pregnancy.<ref name="pmid27672412" />

 
DHT is a [[potency (pharmacology)|potent]] [[agonist]] of the AR, and is in fact the most potent known [[endogenous]] [[ligand (biochemistry)|ligand]] of the receptor. It has an [[affinity (pharmacology)|affinity]] (K<sub>d</sub>) of 0.25 to 0.5&nbsp;nM for the human AR, which is about 2- to 3-fold higher than that of [[testosterone]] (K<sub>d</sub> = 0.4 to 1.0&nbsp;nM)<ref name="MozayaniRaymon2011">{{cite book | first1 = Ashraf | last1 = Mozayani | first2 = Lionel | last2 = Raymon | name-list-format = vanc | title = Handbook of Drug Interactions: A Clinical and Forensic Guide | url = https://books.google.com/books?id=NhBJ6kg_uP0C&pg=PA656 | date = 18 September 2011 | publisher = Springer Science & Business Media|isbn=978-1-61779-222-9|pages=656–}}</ref> and 15–30&nbsp;times higher than that of [[adrenal androgen]]s.<ref name="isbn1-903737-05-2">{{cite book | vauthors = Hemat RA | title = Principles Of Orthomolecularism | publisher = Urotext | location = | year = 2004 | pages = | isbn = 1-903737-05-2 | url = https://books.google.com/?id=ED_xI-CEzFYC&dq=DHT+is+3+times+more+potent+than+testosterone%3B+testosterone+is+5-10+times+more+potent+than+adrenal+androgens | page = 426 }}</ref> In addition, the [[dissociation rate]] of DHT from the AR is 5-fold slower than that of testosterone.<ref>{{cite journal | vauthors = Grino PB, Griffin JE, Wilson JD | title = Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone | journal = Endocrinology | volume = 126 | issue = 2 | pages = 1165–72 | date = February 1990 | pmid = 2298157 | doi = 10.1210/endo-126-2-1165 }}</ref> The [[EC50|EC<sub>50</sub>]] of DHT for activation of the AR is 0.13&nbsp;nM, which is about 5-fold stronger than that of testosterone (EC<sub>50</sub> = 0.66&nbsp;nM).<ref>{{cite book | first = Peter A. | last = Wilderer | name-list-format = vanc | title = Treatise on Water Science, Four-Volume Set | chapter = Bioassays for Estrogenic and Androgenic Effects of Water Constituents | url = https://books.google.com/books?id=HSPtBDpRSXMC&pg=PT1805 | date = 1 September 2010 | publisher = Newnes | isbn = 978-0-444-53199-5 | pages = 1805– }}</ref> In [[bioassay]]s, DHT has been found to be 2.5- to 10-fold more potent than testosterone.<ref name="MozayaniRaymon2011" />

 
Unlike other androgens such as testosterone, DHT cannot be converted by the enzyme [[aromatase]] into an [[estrogen]] like [[estradiol]]. Therefore, it is frequently used in research settings to distinguish between the effects of testosterone caused by binding to the AR and those caused by testosterone's conversion to estradiol and subsequent binding to and activation of ERs.<ref name="pmid10332569">{{cite journal | vauthors = Swerdloff RS, Wang C | title = Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent | journal = Baillière's Clinical Endocrinology and Metabolism | volume = 12 | issue = 3 | pages = 501–6 | date = October 1998 | pmid = 10332569 | doi = 10.1016/s0950-351x(98)80267-x }}</ref> Although DHT cannot be aromatized, it is still converted transformed into metabolites with significant ER affinity and activity.<ref name="pmid22231829" /> These are 3α-androstanediol and 3β-androstanediol, which are predominant agonists of the ERβ.<ref name="pmid22231829" />

 
Unlike testosterone, DHT cannot be [[aromatized]] into an [[estrogen]] like estradiol, and for this reason, has no propensity for estrogenic effects.<ref name="WeinerGallagher2003">{{cite book | first1 = Irving B. | last1 = Weiner | first2 = Michela | last2 = Gallagher | name-list-format = vanc | title=Handbook of Psychology, Biological Psychology|url=https://books.google.com/books?id=07UXE4gG3PcC&pg=PA333|year=2003|publisher=John Wiley & Sons|isbn=978-0-471-38403-8|pages=333–}}</ref>
